TY - JOUR T1 - Dual bronchodilation in real-life COPD management: analysis of patients’ characteristics enrolled in COPD Registry in Russia JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.2423 VL - 56 IS - suppl 64 SP - 2423 AU - Andrey Belevskiy AU - Natalya Kravchenko AU - Larisa Samosudova AU - Olga Ostankova Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/2423.abstract N2 - Introduction: Dual bronchodilation (DB) is a core treatment approach in COPD management. Despite this, real-world data on current practice of DB are limited in Russia.Aims and Objectives: To assess the current clinical practice of DB prescription, disease characteristics and clinical profile of COPD patients based on real-world data.Methods: Data were obtained from the Russian COPD registry: a real-world observational study in outpatient sites (NCT02853383).Results: A total of 2,020 COPD patients were enrolled in the registry. 742 (37%) were treated by fixed DB combination: 43% indacaterol/glycopyrronium (IND/GLY), 42% olodaterol/tiotropium (OLO/TIO), 11% vilanterol/umeclidinium (VIL/UME), 4% formoterol/aclidinium (FOR/ACL). In DB group, the average age was 65.9±9.2 years, 75.5% were men. The mean pack-years of smoking was 39.1, 52% were current smokers. 51% of patients had GOLD B and 58% GOLD II (mean FEV1 58.5 ± 18.8%). The main reported phenotypes were chronic bronchitis (41%), emphysematous (27%), phenotype with cachexia (22%). Phenotype with frequent exacerbations was reported in 2%. The annual rate of COPD exacerbations was 1.05 for IND/GLY; 1.17 for OLO/TIO; 1.38 for VIL/UME and 1.73 for FOR/AKL. The most frequent comorbidities were arterial hypertension (51%), ischemic heart disease (34%), chronic heart failure (10%) and osteoporosis (3%). mMRC ≥ 2 was reported in 76% of patients.Conclusion: The majority of patients treated with DB were in GOLD II and GOLD B, highly symptomatic, with high level of cardio-vascular comorbidity and low risk of COPD exacerbations.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2423.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -